Clinical Trial Update: CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describes CRISPR/Cas9-modified T cells targeting PD-1 and ACE2 for inducing long-term immunity in COVID-19 patients, with Phase 1/Phase 2 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Respiratory Infection

Drugs mentioned

• CRISPR/Cas9-modified Human T Cell (PD-1 and ACE2 Knockout Engineered T Cells)

Snippet

Sponsor: Mahmoud Ramadan mohamed Elkazzaz | Conditions: COVID-19 Respiratory Infection | Phase 1, Phase 2 | Status: UNKNOWN